What's Happening?
The Calibr-Skaggs Institute for Innovative Medicines has announced the advancement of CLF065, a long-acting GLP-2 receptor agonist, into Phase 2 clinical trials for inflammatory bowel diseases (IBD), specifically chronic pouchitis and Crohn's disease.
Chronic pouchitis is a common complication following J-pouch surgery in ulcerative colitis patients, affecting up to 30% of the 200,000 individuals in the U.S. with an ileal pouch. Current treatments focus on reducing inflammation, but CLF065 aims to repair the damaged intestinal lining, addressing epithelial barrier dysfunction. The therapy, developed using Calibr-Skaggs' proprietary stapled-peptide technology, has shown promise in early trials, demonstrating a sustained increase in plasma citrulline, a biomarker of intestinal mucosal growth.
Why It's Important?
This development is significant as it addresses a substantial unmet need in the treatment of IBD, particularly for conditions like chronic pouchitis, which currently lack FDA-approved therapies. By focusing on repairing the intestinal lining, CLF065 could change the treatment paradigm for IBD, complementing existing anti-inflammatory treatments. The success of this therapy could lead to improved quality of life for patients suffering from these debilitating conditions. Additionally, the growing interest in GLP-2 receptor biology highlights the potential for new therapeutic approaches in gastrointestinal diseases, potentially influencing future research and development in the field.
What's Next?
The Phase 2 trials, including the OPUS-Pouch Study and the RESET-CD study, will evaluate the efficacy and safety of CLF065 in patients with chronic pouchitis and Crohn's disease. Positive results could pave the way for broader applications across different IBD phenotypes. The trials are supported by Scripps Research's mission-aligned investment structure, Vx Capital, which aims to advance regenerative clinical-stage programs. If successful, CLF065 could become a key component in the treatment of IBD, offering a new approach that not only reduces inflammation but also repairs the gut lining.
